NCT01349959View on ClinicalTrials.gov

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

August 15, 2011

Primary Completion Date

March 27, 2014

Study Completion Date

November 7, 2023

Conditions
Male Breast CarcinomaRecurrent Breast CarcinomaStage IIIC Breast Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Triple-Negative Breast Carcinoma
Interventions
DRUG

Azacitidine

Given SC

DRUG

Entinostat

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (7)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

55432

Unity Hospital, Fridley

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01349959 - Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter